Does low C-peptide in type 2 diabetes reflect declining beta-cell secretion and larger post-meal glucose excursions?

In type 2 diabetes, monitoring pancreatic health often shifts from measuring insulin to C-peptide, a byproduct of proinsulin cleavage. Because C-peptide has a longer half-life and avoids first-pass hepatic metabolism, it serves as a highly reliable biomarker for endogenous secretory capacity.

C-peptide and beta-cell secretory capacity

C-peptide is co-secreted with insulin in an equimolar ratio, making it an accurate surrogate for the pancreatic output of beta-cells. In clinical research, lower C-peptide levels—both fasting and postprandial (e.g., the P-CPR index)—reflect a significant decline in beta-cell secretory capacity rather than just insulin resistance. This decline is a hallmark of progressive type 2 diabetes, where chronic glucotoxicity leads to cellular exhaustion. For a 70-year-old patient with long-standing disease, low C-peptide often signals a transition from insulin resistance to absolute insulin deficiency, frequently predicting the eventual requirement for exogenous insulin therapy.

Mechanistic impact on glucose excursions

The primary physiological consequence of declining beta-cell secretion is the loss of the "first-phase" insulin response.

• Hepatic Glucose Suppression: In healthy individuals, a rapid insulin surge within 10 minutes of eating suppresses hepatic glucose production (EGP) by 70–80%. When C-peptide levels are low, this surge is absent, allowing the liver to continue releasing glucose while dietary carbohydrates are being absorbed.
• Glycemic Variability: This failure in early-phase secretion directly increases the Mean Amplitude of Glycemic Excursions (MAGE). Studies show a log-linear relationship between endogenous insulin secretion and glucose peaks, meaning that as C-peptide levels drop, the magnitude and duration of post-meal excursions increase disproportionately.
• Peripheral Disposal: Declining secretion also delays peripheral glucose uptake in muscle and adipose tissue, further compounding the duration of postprandial hyperglycemia.

Bottom line

Low C-peptide levels are a robust indicator of diminished beta-cell function, which fundamentally impairs the body's ability to suppress hepatic glucose production and manage post-meal carbohydrate loads, leading to increased glycemic excursions and higher variability.